- Evaxion Biotech ( EVAX ) announced Tuesday the resignation of chief executive officer Lars Staal Wegner.
- The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in clinical pharmacology with over 20 years of working in clinical drug development.
- Most recently, Dr. Norlén was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB, Targinta is a wholly owned subsidiary of Xintela, a publicly listed company on the Nasdaq First North Growth Market Stockholm, Sweden.
- Earlier: Evaxion Biotech to advance DNA vaccine into non-small cell lung cancer indication
For further details see:
Evaxion Biotech announces new CEO as Lars Wegner resigns